Health care execs are sweating over pricing pressure
Public outcry over high prices for drugs and health care services has caught the attention of the people who decide those prices. But that doesn't mean there will be any immediate action. A new survey from investment bank Lazard found that more than half (57%) of 300 U.S. and European health care executives and investors said pricing and reimbursement was the top challenge for them right now.
Data: Lazard Global Healthcare Leaders Study, 2017; Note: September 9 and December 20, 2016 with 213 C-level executives and 87 investors; Chart: Andrew Witherspoon / Axios